Back to results
US 2022/0009945 A1Published application
Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv)
AssigneeAiCuris GmbH & Co. KG
InventorsAlastair DONALD, Andreas URBAN, Susanne BONSMANN
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV replication cycle, compositions comprising such compounds, methods for inhibiting HBV viral replication, methods for treating or preventing HBV infection, and processes and intermediates for making the compounds.
Claims8
A compound of Formula I
- in which
- R1 is phenyl or pyridyl, optionally substituted once, twice, or thrice by halo, C1-C4-alkyl, C3-C6-cycloalkyl, C1-C4-haloalkyl or C≡N
- R2 is H or methyl
- R3 is selected from the group comprising H, D, C1-C6-alkyl, C3-C6-cycloalkyl, C3-C7-heterocycloalkyl, C2-C6-aminoalkyl, SO2—C1-C6-alkyl, SO2—C3-C7-cycloalkyl, SO2—C3-C7-heterocycloalkyl, SO2—C2-C6-hydroxyalkyl, SO2—C2-C6-alkyl-O—C1-C6-alkyl, SO2—C1-C4-carboxyalkyl, SO2-aryl, SO2-heteroaryl, SO2—N(R12)(R13), C(═O)R4, C(═O)N(R12)(R13), C(═O)C(═O)N(R12)(R13), and C2-C6-hydroxyalkyl, optionally substituted with 1, 2, or 3 groups each independently selected from OH, halo, NH2, acyl, SO2CH3, carboxy, carboxyl ester, carbamoyl, substituted carbamoyl, C6-aryl, heteroaryl, C1-C6-alkyl, C3-C6-cycloalkyl, C3-C7-heterocycloalkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-alkyl-O—C1-C6-alkyl, C1-C6-hydroxyalkyl, and C2-C6 alkenyloxy, preferably C1-C6-alkyl, C3-C6-cycloalkyl, C3-C7-heterocycloalkyl and C2-C6-hydroxyalkyl
- R4 is selected from the group comprising C1-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkyl-O—C1-C6-alkyl, C3-C7-cycloalkyl, C1-C4-carboxyalkyl, C3-C7-heterocycloalkyl, C6-aryl, and heteroaryl optionally substituted with 1, 2, or 3 groups each independently selected from OH, halo, NH2, acyl, SO2CH3, SO3H, carboxy, carboxyl ester, carbamoyl, substituted carbamoyl, C6-aryl, heteroaryl, C1-C6-alkyl, C3-C6-cyclo alkyl, C3-C7-heterocyclo alkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-hydroxyalkyl, and C2-C6 alkenyloxy
- R12 and R13 are independently selected from the group comprising H, C1-C6-alkyl, C2-C6-hydroxyalkyl, C2-C6-alkyl-O—C1-C6-alkyl, C3-C7-cycloalkyl, C1-C4-carboxyalkyl, C3-C7-heterocycloalkyl, C6-aryl, and heteroaryl optionally substituted with 1, 2, or 3 groups each independently selected from OH, halo, NH2, acyl, SO2CH3, SO3H, carboxy, carboxyl ester, carbamoyl, substituted carbamoyl, C6-aryl, heteroaryl, C1-C6-alkyl, C3-C6-cycloalkyl, C3-C7-heterocycloalkyl, C1-C6-haloalkyl, C1-C6-alkoxy, C1-C6-hydroxyalkyl, and C2-C6 alkenyloxy
- R12 and R13 are optionally connected to form a C3-C7-heterocycloalkyl ring containing 1 or 2 nitrogen, sulfur or oxygen atoms
- or a pharmaceutically acceptable salt thereof or a solvate or a hydrate of a compound of Formula I or the pharmaceutically acceptable salt thereof or a prodrug of a compound of Formula I or a pharmaceutically acceptable salt or a solvate or a hydrate thereof for use in the prevention or treatment of an HBV infection in a subject.
5 more elements
Dependencies are inferred from the claim text.